State Street SPDR S&P Metals & Mining ETF (XME) upgraded to Buy after 96% YoY rally; P/E 15.4x, strong PEG and bullish ...

Biologics growth and resilient GLP-1 demand support long-term earnings after a 14% pullback; see margin outlook, 2026 profit ...

FDA approval of mitapivat signals a shift in thalassaemia care, offering the first oral option to treat chronic anaemia.